<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-03038R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0001727</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Disease Models</subject><subject>Genetics and Genomics/Epigenetics</subject></subj-group></article-categories><title-group><article-title>Common Variants within <italic>MECP2</italic> Confer Risk of Systemic Lupus Erythematosus</article-title><alt-title alt-title-type="running-head"><italic>MECP2</italic> Confer Risk of Lupus</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sawalha</surname><given-names>Amr H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Webb</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Shizhong</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Jennifer A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaufman</surname><given-names>Kenneth M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kimberly</surname><given-names>Robert P.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alarc&#x000f3;n-Riquelme</surname><given-names>Marta E.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>Judith A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vyse</surname><given-names>Timothy J.</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gilkeson</surname><given-names>Gary S.</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Chan-Bum</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Scofield</surname><given-names>R. Hal</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bae</surname><given-names>Sang-Cheol</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nath</surname><given-names>Swapan K.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Harley</surname><given-names>John B.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>United States Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Rheumatology Section, Imperial College, Hammersmith Hospital, London, United Kingdom</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Division of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America</addr-line></aff><aff id="aff8"><label>8</label><addr-line>Division of Rheumatology, Department of Internal Medicine and the Hospital for Rheumatic Diseases, Hanyang University, Seoul, Republic of Korea</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Jin</surname><given-names>Dong-Yan</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Hong Kong, China</aff><author-notes><corresp id="cor1">&#x0002a;E-mail: <email>amr-sawalha@omrf.ouhsc.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JH AS KK. Performed the experiments: RW KK. Analyzed the data: AS SN SH JK. Contributed reagents/materials/analysis tools: GG JH JJ RK RS TV SB MA CC. Wrote the paper: AS.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>5</day><month>3</month><year>2008</year></pub-date><volume>3</volume><issue>3</issue><elocation-id>e1727</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2007</year></date><date date-type="accepted"><day>5</day><month>2</month><year>2008</year></date></history><copyright-statement>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</copyright-statement><copyright-year>2008</copyright-year><abstract><p>Systemic lupus erythematosus (SLE) is a predominantly female autoimmune disease that affects multiple organ systems. Herein, we report on an X-chromosome gene association with SLE. Methyl-CpG-binding protein 2 (<italic>MECP2</italic>) is located on chromosome Xq28 and encodes for a protein that plays a critical role in epigenetic transcriptional regulation of methylation-sensitive genes. Utilizing a candidate gene association approach, we genotyped 21 SNPs within and around <italic>MECP2</italic> in SLE patients and controls. We identify and replicate association between SLE and the genomic element containing <italic>MECP2</italic> in two independent SLE cohorts from two ethnically divergent populations. These findings are potentially related to the overexpression of methylation-sensitive genes in SLE.</p></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease that affects multiple organs and is associated with significant morbidity and mortality. The disease predominantly affects females with a female to male ratio ranging between 4.3&#x02013;13.6 to 1 <xref ref-type="bibr" rid="pone.0001727-Petri1">&#x0005b;1&#x0005d;</xref>. The etiology of SLE remains incompletely understood, although a number of genetic and environmental factors have been implicated. Strong evidence supports an important role for abnormal T cell DNA methylation in the pathogenesis of SLE <xref ref-type="bibr" rid="pone.0001727-Sawalha1">&#x0005b;2&#x0005d;</xref>. The expression of methylation sensitive genes, such as <italic>ITGAL</italic> (CD11a), <italic>TNFSF7</italic> (CD70), <italic>PRF1</italic> (perforin) and <italic>CD40LG</italic> (CD40L), is increased in T cells from SLE patients, similar to normal T cells treated with DNA methylation inhibitors such as 5-azacytidine <xref ref-type="bibr" rid="pone.0001727-Richardson1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001727-Oelke1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001727-Kaplan1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001727-Lu1">&#x0005b;6&#x0005d;</xref>. Indeed, 5-azacytidine treated T cells are autoreactive in vitro <xref ref-type="bibr" rid="pone.0001727-Richardson2">&#x0005b;7&#x0005d;</xref>, and produce a SLE-like disease upon adoptive transfer into mice <xref ref-type="bibr" rid="pone.0001727-Yung1">&#x0005b;8&#x0005d;</xref>. In active SLE T cells, the expression of DNA methyltransferase 1 (DNMT1), the main enzyme that maintains DNA methylation during cell division, is reduced <xref ref-type="bibr" rid="pone.0001727-Deng1">&#x0005b;9&#x0005d;</xref>, and the promoter sequences of the aforementioned methylation-sensitive genes are hypomethylated <xref ref-type="bibr" rid="pone.0001727-Sawalha1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001727-Lu1">&#x0005b;6&#x0005d;</xref>. DNA methylation suppresses gene expression via several mechanisms including the inability of transcription factors to bind methylated promoter sequences <xref ref-type="bibr" rid="pone.0001727-Bird1">&#x0005b;10&#x0005d;</xref>. Methyl-CpG-binding protein 2 (MECP2) plays a critical role in this process. MECP2 binds methylcytosine residues and recruits histone deacetylase enzymes, which by deacetylating histone residues, increase the charge attraction between DNA and histone proteins and induce a chromatin configuration that is inaccessible for the transcriptional machinery <xref ref-type="bibr" rid="pone.0001727-Jones1">&#x0005b;11&#x0005d;</xref>. Further, DNMT1 associates with and seems to require MECP2 in order to maintain DNA methylation <xref ref-type="bibr" rid="pone.0001727-Kimura1">&#x0005b;12&#x0005d;</xref>.</p><p><italic>MECP2</italic> is located on chromosome Xq28 in man and contains four exons. It is &#x0223c;76 kb in length and is characterized by the presence of a very large intron 2 (&#x0223c;60 kb) and a highly conserved 3&#x02032; UTR (&#x0223c;8.5 kb) <xref ref-type="bibr" rid="pone.0001727-MiltenbergerMiltenyi1">&#x0005b;13&#x0005d;</xref>. The gene encodes a 486 amino acid chromatin-associated protein that consists of three domains; a methyl-binding domain, a transcription repression domain, and a third domain on the C-terminal region that has not been fully functionally characterized <xref ref-type="bibr" rid="pone.0001727-MiltenbergerMiltenyi1">&#x0005b;13&#x0005d;</xref>. The facts that DNA methylation sensitive genes are overexpressed in SLE <xref ref-type="bibr" rid="pone.0001727-Sawalha1">&#x0005b;2&#x0005d;</xref>, and that MECP2 is critical in the transcriptional suppression of methylation sensitive genes <xref ref-type="bibr" rid="pone.0001727-Jones1">&#x0005b;11&#x0005d;</xref>, make <italic>MECP2</italic> an attractive candidate gene for SLE. Using a candidate gene approach and a case-control genetic association study, we report herein on the association of the <italic>MECP2</italic> gene region with SLE in two independent cohorts of SLE patients and controls.</p></sec><sec id="s2"><title>Results</title><p>We initially genotyped 628 Korean female SLE patients and 736 healthy female Korean controls across 21 single nucleotide polymorphisms (SNPs) located within or around <italic>MECP2</italic> (<xref ref-type="table" rid="pone-0001727-t001">Table 1</xref>). Nine SNPs had a minor allele frequency of more than 5&#x00025; in our Korean cohort and were used for further analysis. All 9 SNPs were within expected Hardy-Weinberg proportions in both cases and controls (<xref ref-type="table" rid="pone-0001727-t002">Table 2</xref>). Eight out of the nine SNPs are within the <italic>MECP2</italic> gene and showed significant association with SLE (<xref ref-type="table" rid="pone-0001727-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0001727-g001">Fig. 1</xref>). The SNP having the strongest association in the Korean SLE patients is rs17435 (Chi<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;22.83, OR&#x0200a;&#x0003d;&#x0200a;1.58, p&#x0200a;&#x0003d;&#x0200a;0.0000018) followed by rs1734787 (Chi<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;21.58, OR&#x0200a;&#x0003d;&#x0200a;1.55, p&#x0200a;&#x0003d;&#x0200a;0.0000034), rs1734792 (Chi<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;20.68, OR&#x0200a;&#x0003d;&#x0200a;1.53, p&#x0200a;&#x0003d;&#x0200a;0.0000054) and rs1734791 (Chi<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;18.70, OR&#x0200a;&#x0003d;&#x0200a;1.51, p&#x0200a;&#x0003d;&#x0200a;0.000015). The SNPs rs1734787, rs1734792, and rs1734791 are all in linkage disequilibrium with rs17435 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.88, 0.92, and 0.86, respectively). We next performed haplotype-based association test using Haploview 3.32 software <xref ref-type="bibr" rid="pone.0001727-Barrett1">&#x0005b;14&#x0005d;</xref> and WHAP <xref ref-type="bibr" rid="pone.0001727-Purcell1">&#x0005b;15&#x0005d;</xref>. Three haplotypes (with a frequency of &#x0003e;1&#x00025;) were identified (<xref ref-type="table" rid="pone-0001727-t003">Table 3</xref>). The haplotype &#x0201c;ACTGCAAA&#x0201d; was identified as a disease risk haplotype with a frequency of 82.3&#x00025; in SLE patients compared to 75.3&#x00025; in normal healthy controls (OR&#x0200a;&#x0003d;&#x0200a;1.53, p&#x0200a;&#x0003d;&#x0200a;0.000013). On the other hand, the haplotype &#x0201c;GGAAATCG&#x0201d; is a protective haplotype with a frequency of 16.8&#x00025; in SLE patients and 23.4&#x00025; in normal healthy controls (OR&#x0200a;&#x0003d;&#x0200a;0.66, p&#x0200a;&#x0003d;&#x0200a;0.000027) (<xref ref-type="table" rid="pone-0001727-t003">Table 3</xref>). Frequencies of the homozygous risk genotypes in the haplotype-forming SNPs were analyzed and summarized in <xref ref-type="table" rid="pone-0001727-t004">Table 4</xref>.</p><fig id="pone-0001727-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.g001</object-id><label>Figure 1</label><caption><title>Allelic association results and linkage disequilibrium (LD) plot of the chromosome Xq28 region around the <italic>MECP2</italic> gene.</title><p>The allelic association p values of the SNPs analyzed are shown in the Korean cohort included in this study.</p></caption><graphic xlink:href="pone.0001727.g001"/></fig><table-wrap id="pone-0001727-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.t001</object-id><label>Table 1</label><caption><title>SNPs genotyped in the <italic>MECP2</italic> region in SLE patients and controls</title></caption><graphic id="pone-0001727-t001-1" xlink:href="pone.0001727.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001727-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td align="left" rowspan="1" colspan="1">Position (bp)</td><td align="left" rowspan="1" colspan="1">Alleles</td><td align="left" rowspan="1" colspan="1">Gene</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs2266890</td><td align="left" rowspan="1" colspan="1">152900916</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>TMEM187</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs10127175</td><td align="left" rowspan="1" colspan="1">152937366</td><td align="left" rowspan="1" colspan="1">A/T</td><td align="left" rowspan="1" colspan="1"><italic>IRAK1</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs2075596</td><td align="left" rowspan="1" colspan="1">152950586</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027933</td><td align="left" rowspan="1" colspan="1">152952068</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027935</td><td align="left" rowspan="1" colspan="1">152957662</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027939</td><td align="left" rowspan="1" colspan="1">152963772</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs17435</td><td align="left" rowspan="1" colspan="1">152965174</td><td align="left" rowspan="1" colspan="1">T/A</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs7050901</td><td align="left" rowspan="1" colspan="1">152967504</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs7059306</td><td align="left" rowspan="1" colspan="1">152968184</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs1624766</td><td align="left" rowspan="1" colspan="1">152970348</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs7884370</td><td align="left" rowspan="1" colspan="1">152976075</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734787</td><td align="left" rowspan="1" colspan="1">152978640</td><td align="left" rowspan="1" colspan="1">A/C</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs5987201</td><td align="left" rowspan="1" colspan="1">152983236</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734791</td><td align="left" rowspan="1" colspan="1">152984114</td><td align="left" rowspan="1" colspan="1">T/A</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734792</td><td align="left" rowspan="1" colspan="1">152994254</td><td align="left" rowspan="1" colspan="1">A/C</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs11156611</td><td align="left" rowspan="1" colspan="1">152997368</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs5987204</td><td align="left" rowspan="1" colspan="1">153000782</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs2239464</td><td align="left" rowspan="1" colspan="1">153001625</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs5986954</td><td align="left" rowspan="1" colspan="1">153002489</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1"><italic>MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs5945175</td><td align="left" rowspan="1" colspan="1">153011951</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1"><italic>LOC728653,MECP2</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">rs34371500</td><td align="left" rowspan="1" colspan="1">153850987</td><td align="left" rowspan="1" colspan="1">C/A</td><td align="left" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><table-wrap id="pone-0001727-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.t002</object-id><label>Table 2</label><caption><title>Allele frequencies of SNPs in the <italic>MECP2</italic> gene region genotyped in Korean SLE patients and that have a minor allele frequency of &#x0003e;0.05</title></caption><graphic id="pone-0001727-t002-2" xlink:href="pone.0001727.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001727-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td align="center" rowspan="1" colspan="1">Risk allele</td><td colspan="2" align="left" rowspan="1">Risk allele frequency<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">Chi2</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p value</td><td align="left" rowspan="1" colspan="1">Permutation p value</td><td colspan="2" align="left" rowspan="1">HWE (p exact)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">Controls n (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">Controls</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs2266890</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">804 (72.8)</td><td align="left" rowspan="1" colspan="1">848 (66.6)</td><td align="left" rowspan="1" colspan="1">10.94</td><td align="left" rowspan="1" colspan="1">1.35 (1.13&#x02013;1.61)</td><td align="left" rowspan="1" colspan="1">0.0009</td><td align="left" rowspan="1" colspan="1">0.0029</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2075596</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">1026 (81.7)</td><td align="left" rowspan="1" colspan="1">1103 (74.9)</td><td align="left" rowspan="1" colspan="1">18.05</td><td align="left" rowspan="1" colspan="1">1.49 (1.24&#x02013;1.80)</td><td align="left" rowspan="1" colspan="1">0.000022</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.59</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027933</td><td align="center" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">1025 (81.6)</td><td align="left" rowspan="1" colspan="1">1103 (74.9)</td><td align="left" rowspan="1" colspan="1">17.61</td><td align="left" rowspan="1" colspan="1">1.48 (1.23&#x02013;1.79)</td><td align="left" rowspan="1" colspan="1">0.000027</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.35</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">rs17435</td><td align="center" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">1036 (82.5)</td><td align="left" rowspan="1" colspan="1">1103 (74.9)</td><td align="left" rowspan="1" colspan="1">22.83</td><td align="left" rowspan="1" colspan="1">1.58 (1.31&#x02013;1.90)</td><td align="left" rowspan="1" colspan="1">0.0000018</td><td align="left" rowspan="1" colspan="1">0.00001</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1624766</td><td align="center" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">1044 (83.1)</td><td align="left" rowspan="1" colspan="1">1128 (76.6)</td><td align="left" rowspan="1" colspan="1">17.59</td><td align="left" rowspan="1" colspan="1">1.50 (1.24&#x02013;1.82)</td><td align="left" rowspan="1" colspan="1">0.000027</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734787</td><td align="center" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">1032 (82.2)</td><td align="left" rowspan="1" colspan="1">1101 (74.8)</td><td align="left" rowspan="1" colspan="1">21.58</td><td align="left" rowspan="1" colspan="1">1.55 (1.29&#x02013;1.87)</td><td align="left" rowspan="1" colspan="1">0.0000034</td><td align="left" rowspan="1" colspan="1">0.00003</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734791</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">1032 (82.2)</td><td align="left" rowspan="1" colspan="1">1109 (75.3)</td><td align="left" rowspan="1" colspan="1">18.70</td><td align="left" rowspan="1" colspan="1">1.51 (1.25&#x02013;1.82)</td><td align="left" rowspan="1" colspan="1">0.000015</td><td align="left" rowspan="1" colspan="1">0.00009</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734792</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">1018 (81.1)</td><td align="left" rowspan="1" colspan="1">1085 (73.7)</td><td align="left" rowspan="1" colspan="1">20.68</td><td align="left" rowspan="1" colspan="1">1.53 (1.27&#x02013;1.83)</td><td align="left" rowspan="1" colspan="1">0.0000054</td><td align="left" rowspan="1" colspan="1">0.00003</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2239464</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">1044 (83.1)</td><td align="left" rowspan="1" colspan="1">1127 (76.6)</td><td align="left" rowspan="1" colspan="1">17.94</td><td align="left" rowspan="1" colspan="1">1.51 (1.25&#x02013;1.82)</td><td align="left" rowspan="1" colspan="1">0.000023</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.30</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.</p></fn><fn id="nt102"><label>&#x0002a;</label><p>A total of 628 independent female SLE patients and 736 healthy unrelated female controls were genotyped</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0001727-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.t003</object-id><label>Table 3</label><caption><title><italic>MECP2</italic> haplotype frequencies in the Korean SLE patients and controls.</title></caption><graphic id="pone-0001727-t003-3" xlink:href="pone.0001727.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001727-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Frequency (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">rs2075596</td><td align="left" rowspan="1" colspan="1">rs3027933</td><td align="left" rowspan="1" colspan="1">rs17435</td><td align="left" rowspan="1" colspan="1">rs1624766</td><td align="left" rowspan="1" colspan="1">rs1734787</td><td align="left" rowspan="1" colspan="1">rs1734791</td><td align="left" rowspan="1" colspan="1">rs1734792</td><td align="left" rowspan="1" colspan="1">rs2239464</td><td align="left" rowspan="1" colspan="1">Case</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Haplotype1</bold></td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">82.3</td><td align="left" rowspan="1" colspan="1">75.3</td><td align="left" rowspan="1" colspan="1">1.53 (1.26&#x02013;1.85)</td><td align="left" rowspan="1" colspan="1">0.000013</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Haplotype2</bold></td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">16.8</td><td align="left" rowspan="1" colspan="1">23.4</td><td align="left" rowspan="1" colspan="1">0.66 (0.54&#x02013;0.80)</td><td align="left" rowspan="1" colspan="1">0.000027</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Haplotype3</bold></td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">0.74 (0.36&#x02013;1.50)</td><td align="left" rowspan="1" colspan="1">0.39</td></tr></tbody></table><table-wrap-foot><fn id="nt103"><p>OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0001727-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.t004</object-id><label>Table 4</label><caption><title>Frequencies of homozygous risk allele genotypes in Korean SLE patients compared to controls.</title></caption><graphic id="pone-0001727-t004-4" xlink:href="pone.0001727.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001727-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td align="center" rowspan="1" colspan="1">Risk genotype</td><td colspan="2" align="left" rowspan="1">Risk genotype frequency<xref ref-type="table-fn" rid="nt105">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">Chi2</td><td colspan="2" align="left" rowspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">Controls n (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs2075596</td><td align="center" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">421(67.0)</td><td align="left" rowspan="1" colspan="1">410 (55.7)</td><td align="left" rowspan="1" colspan="1">18.28</td><td align="left" rowspan="1" colspan="1">1.62</td><td align="left" rowspan="1" colspan="1">(1.30&#x02013;2.02)</td><td align="left" rowspan="1" colspan="1">0.00002</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027933</td><td align="center" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">422 (67.2)</td><td align="left" rowspan="1" colspan="1">410 (55.7)</td><td align="left" rowspan="1" colspan="1">18.81</td><td align="left" rowspan="1" colspan="1">1.63</td><td align="left" rowspan="1" colspan="1">(1.31&#x02013;2.03)</td><td align="left" rowspan="1" colspan="1">0.00001</td></tr><tr><td align="left" rowspan="1" colspan="1">rs17435</td><td align="center" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">431 (68.6)</td><td align="left" rowspan="1" colspan="1">412 (56.0)</td><td align="left" rowspan="1" colspan="1">22.98</td><td align="left" rowspan="1" colspan="1">1.72</td><td align="left" rowspan="1" colspan="1">(1.38&#x02013;2.15)</td><td align="left" rowspan="1" colspan="1">0.0000016</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1624766</td><td align="center" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">439 (69.9)</td><td align="left" rowspan="1" colspan="1">427 (58.0)</td><td align="left" rowspan="1" colspan="1">20.66</td><td align="left" rowspan="1" colspan="1">1.68</td><td align="left" rowspan="1" colspan="1">(1.34&#x02013;2.11)</td><td align="left" rowspan="1" colspan="1">0.0000055</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734787</td><td align="center" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">428 (68.2)</td><td align="left" rowspan="1" colspan="1">408 (55.4)</td><td align="left" rowspan="1" colspan="1">23.10</td><td align="left" rowspan="1" colspan="1">1.72</td><td align="left" rowspan="1" colspan="1">(1.38&#x02013;2.15)</td><td align="left" rowspan="1" colspan="1">0.0000015</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734791</td><td align="center" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">428 (68.2)</td><td align="left" rowspan="1" colspan="1">412 (56.0)</td><td align="left" rowspan="1" colspan="1">21.23</td><td align="left" rowspan="1" colspan="1">1.68</td><td align="left" rowspan="1" colspan="1">(1.35&#x02013;2.10)</td><td align="left" rowspan="1" colspan="1">0.0000041</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734792</td><td align="center" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">415 (66.1)</td><td align="left" rowspan="1" colspan="1">398 (54.1)</td><td align="left" rowspan="1" colspan="1">20.29</td><td align="left" rowspan="1" colspan="1">1.66</td><td align="left" rowspan="1" colspan="1">(1.33&#x02013;2.06)</td><td align="left" rowspan="1" colspan="1">0.0000067</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2239464</td><td align="center" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">440 (70.1)</td><td align="left" rowspan="1" colspan="1">426 (57.9))</td><td align="left" rowspan="1" colspan="1">21.70</td><td align="left" rowspan="1" colspan="1">1.70</td><td align="left" rowspan="1" colspan="1">(1.36&#x02013;2.13)</td><td align="left" rowspan="1" colspan="1">0.0000032</td></tr></tbody></table><table-wrap-foot><fn id="nt104"><p>OR, odds ratio; CI, confidence interval.</p></fn><fn id="nt105"><label>&#x0002a;</label><p>A total of 628 independent female SLE patients and 736 healthy unrelated female controls were genotyped</p></fn></table-wrap-foot></table-wrap><p>To replicate our initial results, we next genotyped 1080 European-derived independent SLE patients and 1080 healthy unrelated controls matched for sex and race using the same 21 SNPs in the <italic>MECP2</italic> region (<xref ref-type="table" rid="pone-0001727-t001">Table 1</xref>). Fifteen SNPs had a minor allele frequency of more than 5&#x00025; in our European-derived SLE patients and controls and were used for subsequent analysis. All SNPs that were associated with SLE in Korean patients showed significant association with the same risk alleles in the European-derived cohort (<xref ref-type="table" rid="pone-0001727-t005">Table 5</xref> and <xref ref-type="fig" rid="pone-0001727-g002">Fig. 2</xref>). Similarly, the association with these SNPs is confirmed when only analyzing females in the European-derived SLE patients and controls, with the strongest association observed in rs1734787, rs17435, rs1734791, and rs1734792 (p values&#x0200a;&#x0003d;&#x0200a;0.0016, 0.0017, 0.0020, and 0.0022, respectively). Our haplotype analysis in female European-derived SLE patients and controls also identified 3 haplotypes with the same risk and protective haplotypes as in the Korean cohort (<xref ref-type="table" rid="pone-0001727-t006">Table 6</xref>). Subset analysis of male European-derived SLE patients and controls was not possible due to small sample size.</p><fig id="pone-0001727-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.g002</object-id><label>Figure 2</label><caption><title>Allelic association results and linkage disequilibrium (LD) plot of the chromosome Xq28 region around the <italic>MECP2</italic> gene.</title><p>The allelic association p values of the SNPs analyzed are shown in the European-derived cohort included in this study.</p></caption><graphic xlink:href="pone.0001727.g002"/></fig><table-wrap id="pone-0001727-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.t005</object-id><label>Table 5</label><caption><title>Allele frequencies of <italic>MECP2</italic> SNPs in European-derived SLE patients and controls</title></caption><graphic id="pone-0001727-t005-5" xlink:href="pone.0001727.t005"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001727-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td align="center" rowspan="1" colspan="1">Risk allele</td><td colspan="2" align="left" rowspan="1">Risk allele frequency<xref ref-type="table-fn" rid="nt107">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">Chi2</td><td colspan="2" align="left" rowspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p value</td><td align="left" rowspan="1" colspan="1">Permutation p value</td><td colspan="2" align="left" rowspan="1">HWE (p value)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">Controls n (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">Controls</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs2266890</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">418 (21.2)</td><td align="left" rowspan="1" colspan="1">354 (18.0)</td><td align="left" rowspan="1" colspan="1">6.24</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">(1.04&#x02013;1.43)</td><td align="left" rowspan="1" colspan="1">0.013</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2075596</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">371(18.5)</td><td align="left" rowspan="1" colspan="1">301(15.5)</td><td align="left" rowspan="1" colspan="1">8.59</td><td align="left" rowspan="1" colspan="1">1.28</td><td align="left" rowspan="1" colspan="1">(1.09&#x02013;1.52)</td><td align="left" rowspan="1" colspan="1">0.0034</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.70</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027933</td><td align="center" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">383 (19.1)</td><td align="left" rowspan="1" colspan="1">308 (15.3)</td><td align="left" rowspan="1" colspan="1">9.83</td><td align="left" rowspan="1" colspan="1">1.30</td><td align="left" rowspan="1" colspan="1">(1.10&#x02013;1.53)</td><td align="left" rowspan="1" colspan="1">0.0017</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027935</td><td align="center" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">1879 (93.8)</td><td align="left" rowspan="1" colspan="1">1865 (93.0)</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">1.14</td><td align="left" rowspan="1" colspan="1">(0.89&#x02013;1.46)</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027939</td><td align="center" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">104 (5.5)</td><td align="left" rowspan="1" colspan="1">97 (5.0)</td><td align="left" rowspan="1" colspan="1">0.57</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">(0.84&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">rs17435</td><td align="center" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">500 (24.9)</td><td align="left" rowspan="1" colspan="1">411 (20.5)</td><td align="left" rowspan="1" colspan="1">11.25</td><td align="left" rowspan="1" colspan="1">1.29</td><td align="left" rowspan="1" colspan="1">(1.11&#x02013;1.49)</td><td align="left" rowspan="1" colspan="1">0.0008</td><td align="left" rowspan="1" colspan="1">0.0047</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1624766</td><td align="center" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">497 (24.8)</td><td align="left" rowspan="1" colspan="1">412 (20.5)</td><td align="left" rowspan="1" colspan="1">10.39</td><td align="left" rowspan="1" colspan="1">1.28</td><td align="left" rowspan="1" colspan="1">(1.10&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.0013</td><td align="left" rowspan="1" colspan="1">0.0074</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">rs7884370</td><td align="center" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">109 (5.4)</td><td align="left" rowspan="1" colspan="1">98 (4.9)</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">(0.85&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734787</td><td align="center" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">387 (19.3)</td><td align="left" rowspan="1" colspan="1">307 (15.3)</td><td align="left" rowspan="1" colspan="1">11.15</td><td align="left" rowspan="1" colspan="1">1.32</td><td align="left" rowspan="1" colspan="1">(1.12&#x02013;1.56)</td><td align="left" rowspan="1" colspan="1">0.0008</td><td align="left" rowspan="1" colspan="1">0.0048</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">rs5987201</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">109 (5.4)</td><td align="left" rowspan="1" colspan="1">98 (4.9)</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">(0.85&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734791</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">389 (19.4)</td><td align="left" rowspan="1" colspan="1">311 (15.5)</td><td align="left" rowspan="1" colspan="1">10.43</td><td align="left" rowspan="1" colspan="1">1.31</td><td align="left" rowspan="1" colspan="1">(1.11&#x02013;1.54)</td><td align="left" rowspan="1" colspan="1">0.0012</td><td align="left" rowspan="1" colspan="1">0.0072</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734792</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">388 (19.3)</td><td align="left" rowspan="1" colspan="1">311 (15.5)</td><td align="left" rowspan="1" colspan="1">10.27</td><td align="left" rowspan="1" colspan="1">1.31</td><td align="left" rowspan="1" colspan="1">(1.11&#x02013;1.54)</td><td align="left" rowspan="1" colspan="1">0.0014</td><td align="left" rowspan="1" colspan="1">0.0078</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">rs11156611</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">108 (5.4)</td><td align="left" rowspan="1" colspan="1">98 (4.9)</td><td align="left" rowspan="1" colspan="1">0.51</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">(0.84&#x02013;1.47)</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2239464</td><td align="center" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">475 (23.7)</td><td align="left" rowspan="1" colspan="1">400 (19.9)</td><td align="left" rowspan="1" colspan="1">8.13</td><td align="left" rowspan="1" colspan="1">1.24</td><td align="left" rowspan="1" colspan="1">(1.07&#x02013;1.45)</td><td align="left" rowspan="1" colspan="1">0.0044</td><td align="left" rowspan="1" colspan="1">0.026</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">rs5945175</td><td align="center" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">115 (5.7)</td><td align="left" rowspan="1" colspan="1">103 (5.1)</td><td align="left" rowspan="1" colspan="1">0.70</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">(0.86&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">0.45</td></tr></tbody></table><table-wrap-foot><fn id="nt106"><p>OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.</p></fn><fn id="nt107"><label>&#x0002a;</label><p>A total of 1080 independent cases and 1080 healthy unrelated controls matched for race and sex were genotyped</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0001727-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.t006</object-id><label>Table 6</label><caption><title><italic>MECP2</italic> haplotype frequencies in the European-derived female SLE patients and controls.</title></caption><graphic id="pone-0001727-t006-6" xlink:href="pone.0001727.t006"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001727-t006-6"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">rs2075596</td><td align="left" rowspan="1" colspan="1">rs3027933</td><td align="left" rowspan="1" colspan="1">rs17435</td><td align="left" rowspan="1" colspan="1">rs1624766</td><td align="left" rowspan="1" colspan="1">rs1734787</td><td align="left" rowspan="1" colspan="1">rs1734791</td><td align="left" rowspan="1" colspan="1">rs1734792</td><td align="left" rowspan="1" colspan="1">rs2239464</td><td colspan="2" align="left" rowspan="1">Frequency (&#x00025;)</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Case</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Haplotype1</bold></td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">19.0</td><td align="left" rowspan="1" colspan="1">15.4</td><td align="left" rowspan="1" colspan="1">1.29 (1.08&#x02013;1.53)</td><td align="left" rowspan="1" colspan="1">0.0044</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Haplotype2</bold></td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">77.0</td><td align="left" rowspan="1" colspan="1">81.0</td><td align="left" rowspan="1" colspan="1">0.81 (0.69&#x02013;0.95)</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Haplotype3</bold></td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="1" colspan="1">0.96 (0.70&#x02013;1.34)</td><td align="left" rowspan="1" colspan="1">0.82</td></tr></tbody></table><table-wrap-foot><fn id="nt108"><p>OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><p>The impact of hidden population stratification on our association study was assessed by genomic control (GC) by estimating the inflation factor (&#x003bb;) in the samples. We estimated &#x003bb;&#x0200a;&#x0003d;&#x0200a;1.06 in Korean and 1.08 in European-derived samples, hence no significant population stratification was detected. These results are also corroborated with our population structure estimates; one-population model (homogeneous population) fit better than a two-population model (admixture) for both cohorts.</p></sec><sec id="s3"><title>Discussion</title><p>DNA methylation plays a critical role in tissue differentiation, imprinting, transcriptional suppression of parasitic DNA, silencing of transcriptional &#x0201c;noise&#x0201d;, and X-chromosome inactivation <xref ref-type="bibr" rid="pone.0001727-Bird2">&#x0005b;16&#x0005d;</xref>. Utilizing a candidate gene approach, we first identified significant association with <italic>MECP2</italic> SNPs and SLE in a cohort of Korean SLE patients and controls. We next replicated the association with <italic>MECP2</italic> SNPs in an independent cohort of SLE patients and controls of European descent. Indeed, the disease-associated alleles in rs17435, rs1734787, rs1734792, and rs1734791 (T, C, A, and A respectively) have meta-analysis p values of 1.2&#x000d7;10<sup>&#x02212;8</sup>, 1.6&#x000d7;10<sup>&#x02212;8</sup>, 3.3&#x000d7;10<sup>&#x02212;8</sup>, and 7.2&#x000d7;10<sup>&#x02212;8</sup> respectively (<xref ref-type="table" rid="pone-0001727-t007"><bold>Table 7</bold></xref>). Interestingly, the disease associated alleles in these four <italic>MECP2</italic> SNPs are &#x0223c;4 times more common in Korean as compared to European-derived controls. This might suggest a possible explanation for the higher frequency of SLE in people of Asian descent as compared to Europeans.</p><table-wrap id="pone-0001727-t007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001727.t007</object-id><label>Table 7</label><caption><title>Meta-analysis for risk alleles in SLE-associated <italic>MECP2</italic> SNPs in Korean and European-derived cohorts</title></caption><graphic id="pone-0001727-t007-7" xlink:href="pone.0001727.t007"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001727-t007-7"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td align="left" rowspan="1" colspan="1">Risk allele</td><td align="left" rowspan="1" colspan="1">Heterogeneity P value</td><td colspan="2" align="left" rowspan="1">Meta-analysis OR (95&#x00025;CI)</td><td align="left" rowspan="1" colspan="1">Meta-analysis P value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs2075596</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.25</td><td align="left" rowspan="1" colspan="1">1.38</td><td align="left" rowspan="1" colspan="1">(1.22&#x02013;1.55)</td><td align="left" rowspan="1" colspan="1">2.8&#x000d7;10-07</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3027933</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">1.38</td><td align="left" rowspan="1" colspan="1">(1.22&#x02013;1.56)</td><td align="left" rowspan="1" colspan="1">1.6&#x000d7;10-07</td></tr><tr><td align="left" rowspan="1" colspan="1">rs17435</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">(1.24&#x02013;1.56)</td><td align="left" rowspan="1" colspan="1">1.2&#x000d7;10-08</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1624766</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">1.36</td><td align="left" rowspan="1" colspan="1">(1.21&#x02013;1.52)</td><td align="left" rowspan="1" colspan="1">1.9&#x000d7;10-07</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734787</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">1.42</td><td align="left" rowspan="1" colspan="1">(1.26&#x02013;1.60)</td><td align="left" rowspan="1" colspan="1">1.6&#x000d7;10-08</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734791</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">(1.24&#x02013;1.57)</td><td align="left" rowspan="1" colspan="1">7.2&#x000d7;10-08</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1734792</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">1.40</td><td align="left" rowspan="1" colspan="1">(1.24&#x02013;1.58)</td><td align="left" rowspan="1" colspan="1">3.3&#x000d7;10-08</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2239464</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">(1.20&#x02013;1.51)</td><td align="left" rowspan="1" colspan="1">6.0&#x000d7;10-07</td></tr></tbody></table><table-wrap-foot><fn id="nt109"><p>OR, odds ratio; CI, confidence interval</p></fn></table-wrap-foot></table-wrap><p>MECP2 has been extensively studied in the setting of mental retardation and, particularly, Rett syndrome, an X-linked neurodevelopmental disease that has a cumulative incidence of &#x0223c;1/10,000 females by the age of 12 years <xref ref-type="bibr" rid="pone.0001727-Leonard1">&#x0005b;17&#x0005d;</xref>. In the majority of cases, this syndrome is caused by mutations in the <italic>MECP2</italic> gene <xref ref-type="bibr" rid="pone.0001727-Amir1">&#x0005b;18&#x0005d;</xref>. MECP2-deficient mice demonstrate clinical neurological findings similar to those observed in patients with Rett syndrome <xref ref-type="bibr" rid="pone.0001727-Guy1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001727-Shahbazian1">&#x0005b;20&#x0005d;</xref>, which can be reversed by MECP2 expression <xref ref-type="bibr" rid="pone.0001727-Guy2">&#x0005b;21&#x0005d;</xref>. More recently, mutations in the <italic>MECP2</italic> gene have been recognized in a number of other neuropsychiatric illnesses as well <xref ref-type="bibr" rid="pone.0001727-Shibayama1">&#x0005b;22&#x0005d;</xref>. Identifying MECP2 regulated genes had been a challenge in patients with Rett syndrome <xref ref-type="bibr" rid="pone.0001727-Francke1">&#x0005b;23&#x0005d;</xref>. Recent studies suggest that MECP2 binding to DNA is selective and requires A/T sequences adjacent to methylated CG sites <xref ref-type="bibr" rid="pone.0001727-Klose1">&#x0005b;24&#x0005d;</xref>. In addition to its role in transcriptional regulation, MECP2 interacts with the RNA-binding protein Y box-binding protein 1 (YB-1) and plays a role in RNA splicing <xref ref-type="bibr" rid="pone.0001727-Young1">&#x0005b;25&#x0005d;</xref>.</p><p>Another interesting gene that is in close proximity to <italic>MECP2</italic> is <italic>IRAK1</italic> (Interleukin-1 receptor-associated kinase1). Both <italic>MECP2</italic> and <italic>IRAK1</italic> are on the same haplotype block in combined Japanese and Chinese individuals genotyped in the International HapMap Project (<ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org">www.hapmap.org</ext-link>). Moreover, this haplotype block harbors only <italic>MECP2</italic> and <italic>IRAK1</italic> genes. The pivotal role of <italic>IRAK1</italic> in Toll-like receptor signaling and innate immune response <xref ref-type="bibr" rid="pone.0001727-Gan1">&#x0005b;26&#x0005d;</xref> makes this an important candidate gene for SLE.</p><p>We report on an X-chromosome association in SLE. A role for an X-chromosome gene in this predominantly female disease has long been anticipated. Male patients with Klinefelter's syndrome (47,XXY) have similar risk to develop SLE compared to females (46,XX) (Scofield RH, et al Arthritis and Rheumatism 2003; 48:S383) . Possible explanations for the suggested gene-dose effect are the presence of a SLE susceptibility gene(s) on the X-chromosome, or the overexpression of an X-chromosome gene as a result of loss of random X-chromosome inactivation, or both. X-chromosome inactivation is largely mediated by DNA methylation <xref ref-type="bibr" rid="pone.0001727-Mohandas1">&#x0005b;27&#x0005d;</xref>, and DNA methylation is defective in SLE T cells <xref ref-type="bibr" rid="pone.0001727-Sawalha1">&#x0005b;2&#x0005d;</xref>. Hence, X-chromosome genes in SLE female patients and SLE male patients with Klinefelter's syndrome are available for transcription from both copies on the two X-chromosomes. This mechanism is suggested to explain the observed overexpression of the X-chromosome gene <italic>CD40L</italic> in T cells from female SLE patients <xref ref-type="bibr" rid="pone.0001727-Lu1">&#x0005b;6&#x0005d;</xref>. Our findings provide evidence for SLE association with an X-chromosome region harboring two genes that are intimately involved in regulating the expression of methylation-sensitive genes and in innate immune response.</p><p>In summary, the finding of strong association between the X-chromosome region harboring <italic>MECP2</italic> and SLE suggests an important role for genetic and epigenetic interactions in the pathogenesis of this disease. This might provide more insight for the predominance of SLE in females and suggests a novel mechanism to explain the observed overexpression of methylation-sensitive genes in SLE T cells and the resulting T cell autoreactivity in SLE patients.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>SLE patients and controls</title><p>Korean SLE patients and controls were recruited at the Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea. All patients were of Korean descent and met the 1997 American College of Rheumatology SLE classification criteria. A total of 628 independent female SLE patients and 736 healthy unrelated female controls were studied. No two SLE patients or two controls are blood relatives to avoid intrafamilial correlation bias.</p><p>Another independent cohort of SLE patients of European descent was studied. This cohort consisted of 1080 independent cases and 1080 healthy unrelated controls matched for race and sex and recruited in the SLE genetics studies at the Oklahoma Medical Research Foundation as well as from collaborators in the United States, United Kingdom, and Sweden. This cohort included 928 females and 152 males in each of the case and control groups. All SLE patients met the 1997 American College of Rheumatology SLE classification criteria.</p><p>The study was approved by the Institutional Review Boards of Hanyang University Medical Center, University of Oklahoma Health Sciences Center, and the Oklahoma Medical Research Foundation. Participants in the study gave written informed consent for the genotyping.</p></sec><sec id="s4b"><title>Genotyping</title><p>Twenty one SNPs within or around the <italic>MECP2</italic> gene (<xref ref-type="table" rid="pone-0001727-t001">Table 1</xref>) were genotyped on an Illumina BeadStation 500GX instrument using Illumina Infinum II genotyping assays following manufacturer's recommendations. The SNPs were selected to cover the entire length of <italic>MECP2</italic> and the immediate genetic regions in both the 5&#x02032; and 3&#x02032; ends of <italic>MECP2</italic>. SNPs were selected from the published SNP databases (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/">http://www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>). In general, we selected SNPs that have been validated by at least two groups, that have a minor allele frequency of &#x02265;5&#x00025;, and that had been tested successfully on the Illumina genotyping platform that we used in our study. Genotyping data were only used from samples with a call rate greater than 90&#x00025; of the SNPs screened (98.05&#x00025; of the samples). The average call rate for all samples was 97.18&#x00025;.</p></sec><sec id="s4c"><title>Data analysis</title><p>A population-based case-control statistical design was employed. For each tested SNP, the quality of the genotyping data was assessed by predetermined quality control inclusion criteria (MAF&#x0003e;5&#x00025;, SNP call rate&#x0003e;90&#x00025;, and HWE p value&#x0003e;0.01 among the controls). A Pearson's Chi square was calculated for the frequency of allele associations in cases and controls. P values of &#x0003c;0.05 were considered statistically significant. Odds ratios were calculated under the assumption of normality. Fisher's exact test was used to test for deviation from Hardy-Weinberg equilibrium in the genotyped SNPs in the cases and controls. Permutation p values were calculated to correct for multiple testing using Haploview 3.32 <xref ref-type="bibr" rid="pone.0001727-Barrett1">&#x0005b;14&#x0005d;</xref>. Haplotype frequencies were estimated using the expectation&#x02013;maximization algorithm implemented in Haploview 3.32 <xref ref-type="bibr" rid="pone.0001727-Barrett1">&#x0005b;14&#x0005d;</xref> and WHAP <xref ref-type="bibr" rid="pone.0001727-Purcell1">&#x0005b;15&#x0005d;</xref>. Haplotype-based association analysis was used to perform regression-based omnibus haplotype frequency tests and haplotype-specific tests, implemented in WHAP. We also used pair-wise SNP correlation (r<sup>2</sup>) structure between the two populations to identify the minimum haplotype length which could carry the risk of SLE development. To control for possible confounding due to population stratification, we used genomic control (GC) as well as structured association analysis. A panel of 63 randomly chosen &#x0201c;null&#x0201d; SNPs genotyped on the same Illumina SNP platform was used for GC and for estimating hidden population structure.</p></sec></sec></body><back><ref-list><title>References</title><ref id="pone.0001727-Petri1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>M</given-names></name></person-group><year>2002</year><article-title>Epidemiology of systemic lupus erythematosus.</article-title><source>Best Pract Res Clin Rheumatol</source><volume>16</volume><fpage>847</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">12473278</pub-id></citation></ref><ref id="pone.0001727-Sawalha1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawalha</surname><given-names>AH</given-names></name><name><surname>Richardson</surname><given-names>BC</given-names></name></person-group><year>2005</year><article-title>DNA methylation in the pathogenesis of systemic lupus erythematosus.</article-title><source>Current Pharmacogenomics</source><volume>3</volume><fpage>73</fpage><lpage>78</lpage></citation></ref><ref id="pone.0001727-Richardson1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>BC</given-names></name><name><surname>Strahler</surname><given-names>JR</given-names></name><name><surname>Pivirotto</surname><given-names>TS</given-names></name><name><surname>Quddus</surname><given-names>J</given-names></name><name><surname>Bayliss</surname><given-names>GE</given-names></name><etal/></person-group><year>1992</year><article-title>Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus.</article-title><source>Arthritis Rheum</source><volume>35</volume><fpage>647</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">1376122</pub-id></citation></ref><ref id="pone.0001727-Oelke1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oelke</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Richardson</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>C</given-names></name><etal/></person-group><year>2004</year><article-title>Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors.</article-title><source>Arthritis Rheum</source><volume>50</volume><fpage>1850</fpage><lpage>1860</lpage><pub-id pub-id-type="pmid">15188362</pub-id></citation></ref><ref id="pone.0001727-Kaplan1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>MJ</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Attwood</surname><given-names>J</given-names></name><name><surname>Richardson</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4&#x0002b; lupus T cells.</article-title><source>J Immunol</source><volume>172</volume><fpage>3652</fpage><lpage>3661</lpage><pub-id pub-id-type="pmid">15004168</pub-id></citation></ref><ref id="pone.0001727-Lu1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Tesmer</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Yousif</surname><given-names>N</given-names></name><name><surname>Richardson</surname><given-names>B</given-names></name></person-group><year>In press</year><article-title>Demethylation of CD40LG on the inactive X in T cells from women with lupus.</article-title><source>Journal of Immunology</source></citation></ref><ref id="pone.0001727-Richardson2"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>B</given-names></name></person-group><year>1986</year><article-title>Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4&#x0002b; cells.</article-title><source>Hum Immunol</source><volume>17</volume><fpage>456</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">2432050</pub-id></citation></ref><ref id="pone.0001727-Yung1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>RL</given-names></name><name><surname>Quddus</surname><given-names>J</given-names></name><name><surname>Chrisp</surname><given-names>CE</given-names></name><name><surname>Johnson</surname><given-names>KJ</given-names></name><name><surname>Richardson</surname><given-names>BC</given-names></name></person-group><year>1995</year><article-title>Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo.</article-title><source>J Immunol</source><volume>154</volume><fpage>3025</fpage><lpage>3035</lpage><pub-id pub-id-type="pmid">7533191</pub-id></citation></ref><ref id="pone.0001727-Deng1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>C</given-names></name><name><surname>Kaplan</surname><given-names>MJ</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><year>2001</year><article-title>Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients.</article-title><source>Arthritis Rheum</source><volume>44</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">11229472</pub-id></citation></ref><ref id="pone.0001727-Bird1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>AP</given-names></name><name><surname>Wolffe</surname><given-names>AP</given-names></name></person-group><year>1999</year><article-title>Methylation-induced repression&#x02013;belts, braces, and chromatin.</article-title><source>Cell</source><volume>99</volume><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">10589672</pub-id></citation></ref><ref id="pone.0001727-Jones1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PL</given-names></name><name><surname>Veenstra</surname><given-names>GJ</given-names></name><name><surname>Wade</surname><given-names>PA</given-names></name><name><surname>Vermaak</surname><given-names>D</given-names></name><name><surname>Kass</surname><given-names>SU</given-names></name><etal/></person-group><year>1998</year><article-title>Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.</article-title><source>Nat Genet</source><volume>19</volume><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">9620779</pub-id></citation></ref><ref id="pone.0001727-Kimura1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Shiota</surname><given-names>K</given-names></name></person-group><year>2003</year><article-title>Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>4806</fpage><lpage>4812</lpage><pub-id pub-id-type="pmid">12473678</pub-id></citation></ref><ref id="pone.0001727-MiltenbergerMiltenyi1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miltenberger-Miltenyi</surname><given-names>G</given-names></name><name><surname>Laccone</surname><given-names>F</given-names></name></person-group><year>2003</year><article-title>Mutations and polymorphisms in the human methyl CpG-binding protein MECP2.</article-title><source>Hum Mutat</source><volume>22</volume><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">12872250</pub-id></citation></ref><ref id="pone.0001727-Barrett1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year>2005</year><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="pone.0001727-Purcell1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><year>2007</year><article-title>WHAP: haplotype-based association analysis.</article-title><source>Bioinformatics</source><volume>23</volume><fpage>255</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">17118959</pub-id></citation></ref><ref id="pone.0001727-Bird2"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>AP</given-names></name></person-group><year>1993</year><article-title>Functions for DNA methylation in vertebrates.</article-title><source>Cold Spring Harb Symp Quant Biol</source><volume>58</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">7956040</pub-id></citation></ref><ref id="pone.0001727-Leonard1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>H</given-names></name><name><surname>Bower</surname><given-names>C</given-names></name><name><surname>English</surname><given-names>D</given-names></name></person-group><year>1997</year><article-title>The prevalence and incidence of Rett syndrome in Australia.</article-title><source>Eur Child Adolesc Psychiatry</source><volume>6</volume><issue>Suppl 1</issue><fpage>8</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9452912</pub-id></citation></ref><ref id="pone.0001727-Amir1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>RE</given-names></name><name><surname>Van den Veyver</surname><given-names>IB</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>CQ</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><etal/></person-group><year>1999</year><article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.</article-title><source>Nat Genet</source><volume>23</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">10508514</pub-id></citation></ref><ref id="pone.0001727-Guy1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>J</given-names></name><name><surname>Hendrich</surname><given-names>B</given-names></name><name><surname>Holmes</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>JE</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.</article-title><source>Nat Genet</source><volume>27</volume><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">11242117</pub-id></citation></ref><ref id="pone.0001727-Shahbazian1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shahbazian</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Yuva-Paylor</surname><given-names>L</given-names></name><name><surname>Spencer</surname><given-names>C</given-names></name><name><surname>Antalffy</surname><given-names>B</given-names></name><etal/></person-group><year>2002</year><article-title>Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3.</article-title><source>Neuron</source><volume>35</volume><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">12160743</pub-id></citation></ref><ref id="pone.0001727-Guy2"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>J</given-names></name><name><surname>Selfridge</surname><given-names>J</given-names></name><name><surname>Cobb</surname><given-names>S</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>Reversal of neurological defects in a mouse model of Rett syndrome.</article-title><source>Science</source><volume>315</volume><fpage>1143</fpage><lpage>1147</lpage><pub-id pub-id-type="pmid">17289941</pub-id></citation></ref><ref id="pone.0001727-Shibayama1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibayama</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>EH</given-names><suffix>Jr</suffix></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Glanzmann</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>MECP2 structural and 3&#x02032;-UTR variants in schizophrenia, autism and other psychiatric diseases: a possible association with autism.</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><volume>128</volume><fpage>50</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15211631</pub-id></citation></ref><ref id="pone.0001727-Francke1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Francke</surname><given-names>U</given-names></name></person-group><year>2006</year><article-title>Mechanisms of disease: neurogenetics of MeCP2 deficiency.</article-title><source>Nat Clin Pract Neurol</source><volume>2</volume><fpage>212</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">16932552</pub-id></citation></ref><ref id="pone.0001727-Klose1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klose</surname><given-names>RJ</given-names></name><name><surname>Sarraf</surname><given-names>SA</given-names></name><name><surname>Schmiedeberg</surname><given-names>L</given-names></name><name><surname>McDermott</surname><given-names>SM</given-names></name><name><surname>Stancheva</surname><given-names>I</given-names></name><etal/></person-group><year>2005</year><article-title>DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG.</article-title><source>Mol Cell</source><volume>19</volume><fpage>667</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">16137622</pub-id></citation></ref><ref id="pone.0001727-Young1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>JI</given-names></name><name><surname>Hong</surname><given-names>EP</given-names></name><name><surname>Castle</surname><given-names>JC</given-names></name><name><surname>Crespo-Barreto</surname><given-names>J</given-names></name><name><surname>Bowman</surname><given-names>AB</given-names></name><etal/></person-group><year>2005</year><article-title>Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2.</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><fpage>17551</fpage><lpage>17558</lpage><pub-id pub-id-type="pmid">16251272</pub-id></citation></ref><ref id="pone.0001727-Gan1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><year>2006</year><article-title>Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity.</article-title><source>Immunol Res</source><volume>35</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">17172653</pub-id></citation></ref><ref id="pone.0001727-Mohandas1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohandas</surname><given-names>T</given-names></name><name><surname>Sparkes</surname><given-names>RS</given-names></name><name><surname>Shapiro</surname><given-names>LJ</given-names></name></person-group><year>1981</year><article-title>Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation.</article-title><source>Science</source><volume>211</volume><fpage>393</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">6164095</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This publication was made possible by NIH Grant Number P20-RR015577 from the National Center for Research Resources and by funding from the University of Oklahoma College of Medicine (AHS), NIH Grant Number AI63622 (SKN), and NIH Grants Number AR42460, AI024717, AI31584, AR62277, AR048940, AR0490084, Kirkland Scholar award, Alliance for Lupus Research, and the U.S. Department of Veterans Affairs (JBH).</p></fn></fn-group></back></article> 